Industry

AI-powered real-time information and guidance provides health consumers a better experience, a more inclusive pharmacy network and access to lower cost medications SAN FRANCISCO–(BUSINESS WIRE)–#HealthWayFinding—Transcarent, the One Place for Health and Care™, today announced an expansion of its Pharmacy Care Experience with the addition of SmithRx, a next-generation pharmacy benefits management (PBM) company, as its … [Read more…]

Proposal Provides Stockholders $2.35 per Share in Cash, a 39% Premium to the Unaffected Closing Price, as Well as Potential Additional Value from the Sale of Seer’s Assets via a Contingent Value Right Proposal Provides Stockholders Immediate and Significant Value While Avoiding Further Value Destruction from Continued Abysmal Operating Results Criticizes the Board for Failing … [Read more…]

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea–(BUSINESS WIRE)–#ADC–Third paragraph, second sentence of release should read: Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. (instead of Revenue and operating profit … [Read more…]

Scientists discover that a cell’s ‘mechanical age’ can effectively signal cancer risk. LOS ANGELES–(BUSINESS WIRE)–Researchers at City of Hope®, a cancer research and treatment organization, and the University of California, Berkeley, have created a novel microfluidic platform that can assess women’s breast cancer risk at the cellular level. The first-of-its-kind platform squeezes individual breast epithelial … [Read more…]

BOCA RATON, Fla.–(BUSINESS WIRE)–Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern … [Read more…]

Three-year analysis shows a 98% reduction in severe hypoglycemia, low severe hyperglycemia, and comparable safety in severe renal impairment. PALO ALTO, Calif. & LAS VEGAS–(BUSINESS WIRE)–Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes management across care settings, today announced data presented … [Read more…]

eyonis® LCS 510(k) clearance sets stage for commercialization in the United States New leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout 28% reduction in operating loss in 2025 year‑over‑year, demonstrating strengthened cost discipline and operational efficiency iCRO order backlog reaches a new record at €79.8 million as of March 31, 2026 Cash and … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–#WeareiMR—Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the U.S. commercial launch of its NorthStar® Mapping System. As the first and only cardiac mapping and guidance system designed specifically to harness the power of magnetic resonance (MR) imaging to see the heart throughout a minimally-invasive interventional procedure, NorthStar brings … [Read more…]

Trial will evaluate visugromab’s potential to reverse cancer-associated weight loss and muscle wasting by targeting GDF-15 in patients with advanced solid tumors Fourth Phase 2b study of visugromab broadens CatalYm’s late-stage development program into severe cancer-associated condition impacting treatment outcomes MUNICH & SAN FRANCISCO–(BUSINESS WIRE)–CatalYm today announced that the first patient has been dosed in … [Read more…]

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion INCHEON, Korea–(BUSINESS WIRE)–#ADC–Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by … [Read more…]